|
Monosomy
|
|
0.010 |
GeneticVariation
|
BEFREE |
We report on an infant with JMML with somatic KRAS G12A mutation and monosomy 7 who achieved sustained remission following azacitidine monotherapy.
|
31250550 |
2019 |
|
Palatal Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Furthermore, an additional examination demonstrated an oncogenic KRAS mutation at codon 12 (p.G12D) in both palate tumor and in pleural effusion.
|
30634950 |
2019 |
|
Malignant neoplasm of breast
|
|
0.010 |
GeneticVariation
|
BEFREE |
KRAS G12D point mutation plays an important role in the incidence of non-small-cell lung cancer (NSCLC) as well as colorectal cancer, pancreatic cancer and breast cancer.
|
30876538 |
2019 |
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
KRAS G12D point mutation plays an important role in the incidence of non-small-cell lung cancer (NSCLC) as well as colorectal cancer, pancreatic cancer and breast cancer.
|
30876538 |
2019 |
|
Adenoameloblastoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Although it is unclear why different codon 12 alleles occur in different disease contexts and the complex interactions between tumor genotype and phenotype need clarification, on the basis of our results the presence of KRAS p.G12V/R favors the adenomatoid odontogenic tumor diagnosis in challenging oral neoplasm cases.
|
30643167 |
2019 |
|
Juberg-Marsidi syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
In DNA from biopsies, mosaicism for pathogenic variants, including KRAS p.Ala146Thr in two OES subjects, FGFR1 p.Asn546Lys and KRAS p.Ala146Val in ECCL patients, and KRAS p.Gly12Asp in both SFMS patients, was demonstrated.
|
30891959 |
2019 |
|
Stage II Colon Cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
In one case of mutant stage II colon cancer (KRAS-G12C), the G12D variant was detected in cfDNA instead.
|
31134762 |
2019 |
|
Stage II Colon Cancer AJCC v7
|
|
0.010 |
GeneticVariation
|
BEFREE |
In one case of mutant stage II colon cancer (KRAS-G12C), the G12D variant was detected in cfDNA instead.
|
31134762 |
2019 |
|
Stage II Colon Cancer AJCC v8
|
|
0.010 |
GeneticVariation
|
BEFREE |
In one case of mutant stage II colon cancer (KRAS-G12C), the G12D variant was detected in cfDNA instead.
|
31134762 |
2019 |
|
Hepatitis B
|
|
0.010 |
GeneticVariation
|
BEFREE |
With hepatitis B virus double mutation (HBVDM) and KRAS G12V point mutation as model double mutations, it is shown that PEPS was able to detect double-stranded HBVDM and KRAS with 70% detection efficiency or better at concentration as low as 10<sup>-19</sup> M against single-stranded mutation detection at the same concentrations, which was validated by the following in situ fluorescent reporter microspheres (FRMs) detection as well as microscopic visualization of the FRMs bound to the captured mutant on the PEPS surface.
|
30142581 |
2018 |
|
Embryonal Rhabdomyosarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma.
|
30353028 |
2018 |
|
Carcinoma, Papillary
|
|
0.010 |
GeneticVariation
|
BEFREE |
A KRAS G12V mutation was detected in the plasma of 1 patient with stage IVA papillary carcinoma whose tissue contained the same mutation.
|
29498908 |
2018 |
|
Colon Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Furthermore, EGF‑ETA was just as potent in HCT116 (KRAS G13D) and SW480 (KRAS G12V) colon cancer cell lines harbouring KRAS hyperactivating mutations when compared to KRAS wild‑type HT29 colon cancer cells.
|
30226622 |
2018 |
|
Adenocarcinoma, intestinal type
|
|
0.010 |
GeneticVariation
|
BEFREE |
The genetic analysis showed that only 1 sinonasal ITAC (1/7) showed KRAS c.35G>C, p.(Gly12Ala) mutation, whereas BRAF and NRAS genes were wild type.
|
27258560 |
2018 |
|
Childhood Embryonal Rhabdomyosarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma.
|
30353028 |
2018 |
|
Chronic myeloproliferative disorder
|
|
0.010 |
GeneticVariation
|
BEFREE |
Further, one of the patients (c.35G>A; p.(Gly12Asp)) had a myeloproliferative disorder, and one subject (c.34G>C; p.(Gly12Arg)) exhibited an uncharacterized brain tumour.
|
28594414 |
2017 |
|
Skin lesion
|
|
0.010 |
GeneticVariation
|
BEFREE |
Whole-exome sequencing revealed a low-level heterozygous mutation of the KRAS gene (c.35C > T; p.G12D, 19%) in the skin lesion sample.
|
29381910 |
2017 |
|
Myeloproliferative disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
Further, one of the patients (c.35G>A; p.(Gly12Asp)) had a myeloproliferative disorder, and one subject (c.34G>C; p.(Gly12Arg)) exhibited an uncharacterized brain tumour.
|
28594414 |
2017 |
|
Adenocarcinoma of pancreas
|
|
0.010 |
GeneticVariation
|
BEFREE |
Mice harboring a G12D activating Kras mutation are among the most heavily studied models in the field of pancreatic adenocarcinoma (PDAC) research. miRNAs are differentially expressed in PDAC from patients and mouse models of PDAC.
|
27541609 |
2017 |
|
Mammary Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Application of these signatures to breast tumor gene expression data identified two novel discrete phenotypes characterized by concordant, aberrant activation of either the HER2, IGF1R, and AKT pathways ("the survival phenotype") or the EGFR, KRAS (G12V), RAF1, and BAD pathways ("the growth phenotype").
|
28446242 |
2017 |
|
Adenomatous Polyposis Coli
|
|
0.010 |
GeneticVariation
|
BEFREE |
These results demonstrated the validity of the G22Cre; Apc(flox/flox) ;Kras (G12D) mice as a new mouse model with oncogenic Kras activation.
|
26361962 |
2016 |
|
Disseminated Malignant Neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
GTPase-impairing somatic mutations in RAS genes, such as KRAS(G12D), are among the most common oncogenic events in metastatic cancer.
|
26549032 |
2016 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
KRAS(G12D) T-ALLs do not show constitutive GTP loading of Ras.
|
26549032 |
2016 |
|
Childhood Angiosarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Angiosarcoma showed a KRAS G12D point mutation, which is considered to be characteristic of vinyl chloride-induced angiosarcoma.
|
27544804 |
2016 |
|
Hemangiosarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Angiosarcoma showed a KRAS G12D point mutation, which is considered to be characteristic of vinyl chloride-induced angiosarcoma.
|
27544804 |
2016 |